Long-term neuroleptic treatments counteract dopamine D2 agonist inhibition of adenylate cyclase but do not affect pertussis toxin ADP-ribosylation in the rat brain

Neurochemistry International

Volumn 28, Issue 2, 1996, Pages 161-168

  Okada, Fumihiko ^a   Ito, Akihiro ^a   Horikawa, Tamaki ^a   Tokumitsu, Yukiko ^a   Nomura, Yasuyuki ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENYLATE CYCLASE; CHLORPROMAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; HALOPERIDOL; NEUROLEPTIC AGENT; PERTUSSIS TOXIN; SPIPERONE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DRUG INHIBITION; ENZYME INHIBITION; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALIA;

EID: 0030046095     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-0186(95)00074-7     Document Type: Article

References (41)

1. Burt D. R., Creese I. and Snyder S. H. (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196, 326-328.
2. Chiara G. D., Morelli M. and Consolo S. (1994) Modulatory functions of neurotransmitters in the striatum: ach/ dopamine/NMDA interactions. Trends Neurosci. 17, 228-233.
3. Clement-Cormier Y. C., Kebabian J. W., Petzold G. L. and Greengard P. (1974) Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc. natn. Acad. Sci. U.S.A. 71, 1113-1117.
4. Crane G. E. (1973) Persistent dyskinesia. Br. J. Psychiat. 122, 395-405.
5. Creese I., Burt D. R. and Snyder S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
6. Gupta S. K. and Mishra R. K. (1992) Effects of chronic treatment of haloperidol and clozapine on levels of G-protein subunits in rat striatum. J. Molec. Neurosci. 3, 197-201.
7. Hepler J. R. and Gilman A. G. (1992) G proteins. Trends Biochem. Sci. 17, 383-387.
8. Honma M., Satoh T., Takezawa J. and Ui M. (1977) An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem. Med. 18, 257-273.
9. Iversen L. L. (1975) Dopamine receptors in the brain. A dopamine-sensitive adenylate cyclase models synaptic receptors, illuminating antipsychotic drug action. Science 188, 1084-1089.
10. Jakobs K. H., Aktories K., and Schultz G. (1984) Mechanisms and components involved in adenylate cyclase inhibition by hormones. Adv. Cyclic Nucleotides Protein Phosphorylation Res. 17, 135-143.
11. Jenner P., Kerwin R., Rupniak N. M. J., Murugaiah K., Hall M. D., Fleminger S. and Marsden C. D. (1983) Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats. J. Neural Transm. (Suppl.) 18, 205-212.
12. Katada T. and Ui M. (1982) Direct modification of the membrane adenylate cyclase system by islet-activating protein due to ADP-ribosylation of a membrane protein. Proc. natn. Acad. Sci. U.S.A. 79, 3129-3133.
13. Katada T., Oinuma M. and Ui M. (1986) Two guanine nucleotide-binding proteins in rat brain serving as the specific substrate of islet-activating protein, pertussis toxin. Interaction of the α-subunits with βγ-subunits in development of their biological activities. J. biol. Chem. 261, 8182-8189.
14. Kaneno S., Watanabe S., Toru M. and Shimazono Y. (1978) Different dopamine stimulation of adenylate cyclase in striatum and mesolimbic area of rats treated with chronic chlorpromazine. Brain Res. 152, 396-400.
15. Kebabian J. W. and Calne D. B. (1979) Multiple receptors for dopamine. Nature 277, 93-96.
16. Klawans H. L. (1973) The pharmacology of tardive dyskinesias. Am. J. Psychiat. 130, 82-86.
17. Klawans H. L. and Rubovits R. (1972) An experimental model of tardive dyskinesia. J. Neural Transm. 33, 235-246.
18. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265-275.
19. 2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology 26, 477-480.
20. Murayama T. and Ui M. (1983) Loss of the inhibitory function of the guanine nucleotide regulatory component of adenylate cyclase due to its ADP ribosylation by islet-activating protein, pertussis toxin, in adipocyte membranes. J. biol. Chem. 258, 3319-3326.
21. Okada F., Crow T. J. and Roberts G. W. (1990) G-proteins (Gi.Go) in the basal ganglia of control and schizophrenic brain. J. Neural Transm. (GenSect.) 79, 227-234.
22. Okada F., Crow T. J. and Roberts G. W. (1991) G proteins (Gi,Go) in the medical temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J. Neural Transm. (GenSect.) 84, 147-153.
23. 2 inhibition (dual control) of adenylate cyclase by dopamine in rat striatum. Neurochem. Int. 24, 23-27.
24. Okada F., Takahashi N., Ito A., Tokumitsu Y. and Nomura Y. (1994) Acceleration of desipramine-induced changes on the dopamine receptor-coupled adenylate cyclase system by pertussis toxin. J Neural Transm. (GenSect.) 98, 133-142.
25. Olianas M. C. and Onali P. (1987) Supersensitivity of striatal D2 dopamine receptors mediating inhibition of adenylate cyclase and stimulation of guanosine triphosphate following chronic administration of haloperidol in mice. Neurosci. Lett. 78, 349-354.
26. Onali P., Olianas M. C. and Gessa G. L. (1985) Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum. Molec. Pharmac. 28, 138-145.
27. s to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic anti-depressant treatment. Molec. Pharmac. 36, 803-808.
28. Quenzer L. F., Galli C. L. and Neff N. H. (1977) Activation of the migrostriatal dopaminergic pathway by injection of cholera enterotoxin into the substantia nigra. Science 195, 78-80.
29. Rotrosen J., Friedman E. and Gershon S. (1975) Striatal adenylate cyclase activity following reserpine and chronic chlorpromazine administration in rats. Life Sci. 17, 563-568.
30. Roufogalis B. D., Thornton M. and Wade D. N. (1976) Nucleotide requirement of dopamine sensitive adenylate cyclase in synaptosomal membranes from the striatum of rat brain. J. Neurochem. 27, 1533-1535.
31. Seeman P. (1981) Brain dopamine receptors. Pharmac. Rev. 32, 229-335.
32. Seeman P. and Van Tol H. H. M. (1994) Dopamine receptor pharmacology. Trends Pharmac. Sci. 15, 264-270.
33. Seeman P., Lee T., Chau-Wong M. and Wong K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
34. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. natn. Acad. Sci. U.S.A. 86, 10,156-10,160.
35. 4 receptors elevated in schizophrenia. Nature 365, 441-445.
36. Spano P. F., Govoni S. and Trabucchi M. (1978) Studies on the pharmacological system. In: Advances in Biochemical Psychopharmacology (Roberts P. J., Woodruff G. N. and Iversen L. L., eds), Vol. 19, pp. 155-165. Raven Press. New York.
37. Tarsey D. and Baldessarini R. J. (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13, 927-940.
38. Taubes G. (1994) Will new dopamine receptors offer a key to schizophrenia? Science 265, 1034-1035.
39. Ui M. (1984) Islet-activating protein, pertussis toxin. A probe for functions of the inhibitory guanine nucleotide regulatory component of adenylate-cyclase. Trends Pharmac. Sci. 5, 277-279.
40. Vonvoigtlander P. F., Losey E. G. and Triezenberg H. J. (1975) Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J. Pharmac. exp. Ther. 193, 88-94.
41. Yamamoto H., Tomita U., Mikuni M., Kobayashi I., Kagaya A., Katada T. Ui M. and Takahashi K. (1992) Direct activation of purified G-type GTP binding protein by tricyclic antidepressants. Neurosci. Lett. 139, 194-196.